Abstract: The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

Abstract: The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

Abstract: The present invention provides immunomodulatory combinations that includes an IRM component and a therapeutic agent, each in an amount that, when in combination with the other, is effective for inducing an immune response in a subject.

Abstract: Dye labeled imidazonaphthyridine, imidazopyridine and imidazoquinoline compounds having immune response modulating activity are disclosed. The compounds arc useful, inter alia, for determining the binding and/or receptor sites of the molecules.

Abstract: The invention provides a method of activating neutrophils. Generally, the method includes contacting neutrophils with a neutrophil-activating IRM compound and/or a TLR8-selective agonist in an amount effective to activate the neutrophils. In some embodiments, the method may be used to treat a condition treatable by activating neutrophils. In another aspect, the invention provides pharmaceutical compositions that generally include a neutrophil-activating IRM compound and/or a TLR8-selective agonist, or a pharmaceutically acceptable form thereof, in an amount effective to activate neutrophils.

Abstract: The present invention provides immunostimulatory combinations and methods. Generally, the immunostimulatory combinations include a topical formulation of an IRM compound and a pharmaceutical composition. Generally, the methods include administering (a) a topical formulation of an IRM compound, and (b) a pharmaceutical composition to an administration site of a subject.

Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokin induction and eosinophilia, as well as enhance TH1 immune response.

Abstract: The disclosure provides methods for the treatment and prevention of periodontal disease. In preferred embodiments, the invention provides for local treatment of periodontal tissues with a pharmaceutical composition including an immune response modifier (IRM) selected from the group of immune response modifiers comprising imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphtyridine amines, oxazoloquinoline amines, thiazoloquinoline amines and 1,2-bridged imidazopyridine amines.

Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.

Abstract: Methods for identifying a compound that activates a TLR-mediated cellular signaling pathway is disclosed. The method includes (a) exposing a TLR-positive cell culture to a test compound and measuring a TLR-mediated cellular response; (b) exposing a TLR-negative cell culture to a test compound and measuring a TLR-mediated cellular response; and (c) identifying the test compound as an IRM if the cellular response in the TLR-positive cell culture is greater than the cellular response of the TLR-negative cell culture. Methods of eliciting a TLR-mediated cellular response are also disclosed. Such methods include administration of an IRM compound to an IRM-responsive cell so that the IRM compounds affects at least one TLR-mediate cellular signaling pathway.

Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.

Abstract: Dye labeled imidazonaphthyridine, imidazopyridine and imidazoquinoline compounds having immune response modulating activity are disclosed. The compounds are useful, inter alia, for determining the binding and/or receptor sites of the molecules.

Abstract: A method of inducing the maturation of dendritic cells by stimulating immature dendritic cells with an imidazoquinoline type immune response modifying compound. Dendritic cells that have been matured in this manner display increased antigen presenting ability and may be used as immunotherapeutic agents.

Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.

Abstract: The present invention relates to methods of maturing plasmacytoid dendrites cells using immune response modifier molecules. The present invention also relates to methods of detecting biological activities of matured plasmacytoid dendritic cells and methods of using mature plasmacytoid dendritic cells for therapeutic or prophylactic purposes.

Abstract: A method of inducing the maturation of dendritic cells by stimulating immature dendritic cells with an imidazoquinoline type immune response modifying compound. Dendritic cells that have been matured in this manner display increased antigen presenting ability and may be used as immunotherapeutic agents.

Abstract: Dye labeled imidazonaphthyridine, imidazopyridine and imidazoquinoline compounds having immune response modulating activity are disclosed. The compounds are useful, inter alia, for determining the binding and/or receptor sites of the molecules.

Abstract: Methods for screening for compounds that selectively induce IFN-&60 production and methods for ameliorating conditions in a patient using a small molecule that selectively induces the production of IFN-&agr; are disclosed.

Abstract: Dye labeled imidazonaphthyridine, imidazopyridine and imidazoquinoline compounds having immune response modulating activity are disclosed. The compounds are useful, inter alia, for determining the binding and/or receptor sites of the molecules.